Sugi Predict

Sugi Predict / Compounds / SCHEMBL2683501

SCHEMBL2683501

SCHEMBL2683501

Nc1ccnc(S(=O)(=O)O)c1[N+](=O)[O-]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ PLCG1 P19174 1/20 0.38
▸ DNMT1 P26358 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ USP2 O75604 1/20 0.37
▸ KEAP1 Q14145 1/20 0.37
▸ NFE2L2 Q16236 1/20 0.37
▸ NPY1R P25929 12/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ PAX8 Q06710 1/20 0.34
▸ TSHR P16473 2/20 0.33
▸ NT5E P21589 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8567904 0.85 CA2 (0.39) KMT2AMEN1USP2KEAP1NFE2L2
SCHEMBL6095568 0.81 MEN1 (0.36) GAAKMT2AMEN1NPY1RKDM4E
SCHEMBL6095575 0.81 MEN1 (0.36) GAAKMT2AMEN1NPY1RKDM4E
SCHEMBL597274 0.77 KDM4E (0.40) NSD2GAAPLCG1DNMT1CASP6
SCHEMBL8601717 0.76 ALDH1A1 (0.36) L3MBTL1KMT2AMEN1USP2KEAP1
SCHEMBL4064206 0.75 MEN1 (0.41) GAAL3MBTL1KMT2AMEN1USP2
SCHEMBL5126783 0.75 PKM (0.42) KMT2AMEN1USP2KEAP1NFE2L2
SCHEMBL8569457 0.75 TXNRD1 (0.49) KMT2AMEN1NPY1RRAB9ACYP3A4
SCHEMBL8565282 0.75 KDM4E (0.42) L3MBTL1KMT2AMEN1USP2KEAP1
SCHEMBL8562662 0.75 KDM4E (0.39) GAAL3MBTL1KMT2AMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137814-A1 Synthesis of diaminodinitropyridine DUPONT SAFETY & CONSTRUCTION, INC. 2009-05-28 — — US claimed
US-20120116046-A1 SYNTHESIS OF DIAMINODINITROPYRIDINE E. I. DU PONT DE NEMOURS AND COMPANY (US) 2012-05-10 — — US disclosed
US-20090137814-A1 Synthesis of diaminodinitropyridine DUPONT SAFETY & CONSTRUCTION, INC. 2009-05-28 — — US disclosed
US-7098221-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-08-29 — — US disclosed
US-20050282854-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2005-12-22 — — US disclosed
US-6969722-B2 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-11-29 — — US disclosed
US-6903113-B2 Urea substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-06-07 — — US disclosed
US-6878719-B2 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-12 — — US disclosed
US-20040186128-A1 Amide substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-23 — — US disclosed
EP-1453829-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-08 — — EP disclosed
WO-2003050117-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 — — WO disclosed
WO-2003050119-A2 UREA SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 — — WO disclosed
US-6545017-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 — — US disclosed
US-6545016-B1 Inducing cytokine biosynthesis; treating a viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2003-04-08 — — US disclosed
US-6525064-B1 Immune response modifiers; can induce the biosynthesis of various cytokines; 3M INNOVATIVE PROPERTIES COMPANY 2003-02-25 — — US disclosed
US-20020107262-A1 SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-08 — — US disclosed
WO-2002046194-A2 SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 — — WO disclosed
EP-0735025-B1 Process for producing aminonitropyridines SUMITOMO CHEMICAL CO (JP) 1998-07-01 — — EP disclosed
US-5648496-A AMINATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-15 — — US disclosed
EP-0735025-A1 Process for producing aminonitropyridines SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186128-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG NSD2 616/4885GAA 2401/4885PLCG1 3577/4885
US-20050282854-A1 Amide substituted imidazopyridines IRF3, EIF2AK2, IFNG NSD2 616/4885GAA 2401/4885PLCG1 3577/4885
US-20020107262-A1 SUBSTITUTED IMIDAZOPYRIDINES IRF3, IFNG, EIF2AK2 NSD2 981/4885GAA 2527/4885PLCG1 4093/4885
US-20090137814-A1 Synthesis of diaminodinitropyridine ODC1, NOS1, SRM NSD2 1321/4885GAA 3960/4885PLCG1 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.